Pterygium

Summary

Pterygium (MONDO:0005085) is a disease and 94 clinical trials. Top therapeutic interventions include bevacizumab, fluorouracil, and brimonidine tartrate. A subtype of benign conjunctival neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 94

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pterygium
Mondo ID	MONDO:0005085
EFO	EFO:0000678
MeSH	D011625
DOID	DOID:0002116
ICD-10-CM	H11.0
ICD-11	1207385905
NCIT	C133744
SNOMED CT	77489003
UMLS	C0033999
MedGen	46202
Is cancer (heuristic)	no

Also known as: pterygium of conjunctiva and cornea

Data availability: 2 cell lines.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › conjunctival disorder › conjunctival tumor › benign conjunctival neoplasm › pterygium

Related subtypes (2): conjunctival nevus, lipoma of the conjunctiva

Subtypes (3): double pterygium, conjunctival pterygium, familial pterygium of the conjunctiva

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

7 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Bevacizumab	Phase 3
Fibrin	Phase 3
Histamine	Phase 3
Tranilast	Phase 3
Cyclosporine	Phase 2
Mitomycin	Phase 2
Ranibizumab	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 94.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	54
PHASE3	11
PHASE4	10
PHASE2	9
PHASE1	6
PHASE2/PHASE3	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT01736449	PHASE4	COMPLETED	Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
NCT02530801	PHASE4	UNKNOWN	Strategies for Management of Recurrent Pterygium
NCT02641132	PHASE4	UNKNOWN	Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.
NCT03037736	PHASE4	WITHDRAWN	Outpatient Performed Pterygium Surgery Study
NCT03521791	PHASE4	COMPLETED	Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
NCT04022811	PHASE4	COMPLETED	Effect of Bromfenac on Pain Related to Pterygium Surgery
NCT04403516	PHASE4	COMPLETED	Dextenza in Pterygium Surgery
NCT05314673	PHASE4	COMPLETED	Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients
NCT05978687	PHASE4	COMPLETED	The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision
NCT05456425	PHASE3	ACTIVE_NOT_RECRUITING	A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT00320762	PHASE3	COMPLETED	Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital
NCT00320957	PHASE3	COMPLETED	Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital
NCT00321035	PHASE3	COMPLETED	Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital
NCT00326560	PHASE3	UNKNOWN	Comparison of Glue With Sutures for Pterygium Surgery
NCT00346450	PHASE3	COMPLETED	Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
NCT00457223	PHASE2/PHASE3	COMPLETED	To Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation
NCT00478790	PHASE3	UNKNOWN	Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People’s Hospital
NCT01003613	PHASE3	COMPLETED	Evaluation of Tranilast to Treat Pterygium Before Excision
NCT01024257	PHASE3	COMPLETED	Pterygium Treatment Using Single Beta-therapy as Adjuvant Treatment Compared to Conjunctival Autograft
NCT01311960	PHASE3	COMPLETED	Topical Bevacizumab for Preventing Recurrent Pterygium
NCT01380678	PHASE3	UNKNOWN	Intralesional Bevacizumab Injection on Primary Pterygium
NCT01744756	PHASE2/PHASE3	COMPLETED	Subconjunctival Bevacizumab and Recurrent Pterygium
NCT02342392	PHASE2/PHASE3	COMPLETED	Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
NCT00592176	PHASE2	COMPLETED	The Effect of Bevacizumab (Avastin) on Pterygium
NCT01109056	PHASE2	COMPLETED	Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium
NCT01115517	PHASE2	COMPLETED	Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
NCT01250353	PHASE2	COMPLETED	The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction
NCT02148016	PHASE1/PHASE2	UNKNOWN	Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation
NCT02486484	PHASE2	UNKNOWN	Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
NCT02782260	PHASE2	UNKNOWN	Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium
NCT03049852	PHASE2	COMPLETED	Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
NCT03533244	PHASE2	COMPLETED	A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
NCT05794204	PHASE2	COMPLETED	RMP-A03 Ocular Suspension in Patients With Pterygium
NCT00155402	PHASE1	WITHDRAWN	The Application of Fibrin Glue in Ocular Surface Diseases
NCT00344201	PHASE1	COMPLETED	Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery
NCT00768963	PHASE1	COMPLETED	Ranibizumab for the Inhibition of Neovascularization in Pterygia
NCT01169909	PHASE1	COMPLETED	Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
NCT01686529	PHASE1	COMPLETED	Bevacizumab for Primary Pterygium Treatment
NCT05627947	PHASE1	COMPLETED	Comparison Between Topical Mitomycin C and Cyclosporine

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	6
FLUOROURACIL	4	2
BRIMONIDINE TARTRATE	4	1
BROMFENAC	4	1
DIPYRIDAMOLE	4	1
MITOMYCIN	4	1
OXYGEN	4	1
PREDNISOLONE	4	1
TERFENADINE	4	1
FIBRIN	3	2
CHEMBL4071382	0	3
CHEMBL5175144	0	3
S-ROLIPRAM	0	3
CHEMBL4854670	0	1
3-AMINO- 3-DEOXYTHYMIDINE	0	1